Meptazinol

DB13478

small molecule experimental

Deskripsi

Struktur Molekul 2D

Berat 233.355
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

915 Data
Buprenorphine Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.
Hydrocodone The therapeutic efficacy of Hydrocodone can be decreased when used in combination with Meptazinol.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.
Magnesium sulfate The therapeutic efficacy of Meptazinol can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Meptazinol may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.
Orphenadrine Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.
Pramipexole Meptazinol may increase the sedative activities of Pramipexole.
Ropinirole Meptazinol may increase the sedative activities of Ropinirole.
Rotigotine Meptazinol may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Meptazinol.
Sodium oxybate Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol The therapeutic efficacy of Tapentadol can be decreased when used in combination with Meptazinol.
Thalidomide Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Alvimopan The risk or severity of adverse effects can be increased when Meptazinol is combined with Alvimopan.
Desmopressin The risk or severity of hyponatremia can be increased when Meptazinol is combined with Desmopressin.
Morphine The therapeutic efficacy of Morphine can be decreased when used in combination with Meptazinol.
Codeine The therapeutic efficacy of Codeine can be decreased when used in combination with Meptazinol.
Hydromorphone The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Meptazinol.
Meperidine The therapeutic efficacy of Meperidine can be decreased when used in combination with Meptazinol.
Oxycodone The therapeutic efficacy of Oxycodone can be decreased when used in combination with Meptazinol.
Dextropropoxyphene The therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Meptazinol.
Naltrexone The therapeutic efficacy of Meptazinol can be decreased when used in combination with Naltrexone.
Sufentanil The therapeutic efficacy of Sufentanil can be decreased when used in combination with Meptazinol.
Alfentanil The therapeutic efficacy of Alfentanil can be decreased when used in combination with Meptazinol.
Fentanyl The therapeutic efficacy of Fentanyl can be decreased when used in combination with Meptazinol.
Levorphanol The therapeutic efficacy of Levorphanol can be decreased when used in combination with Meptazinol.
Remifentanil The therapeutic efficacy of Remifentanil can be decreased when used in combination with Meptazinol.
Diphenoxylate The therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Meptazinol.
Oxymorphone The therapeutic efficacy of Oxymorphone can be decreased when used in combination with Meptazinol.
Dezocine The therapeutic efficacy of Dezocine can be decreased when used in combination with Meptazinol.
Methadyl acetate The therapeutic efficacy of Methadyl acetate can be decreased when used in combination with Meptazinol.
Dihydroetorphine The therapeutic efficacy of Dihydroetorphine can be decreased when used in combination with Meptazinol.
Diamorphine The therapeutic efficacy of Diamorphine can be decreased when used in combination with Meptazinol.
Bezitramide The therapeutic efficacy of Bezitramide can be decreased when used in combination with Meptazinol.
Ethylmorphine The therapeutic efficacy of Ethylmorphine can be decreased when used in combination with Meptazinol.
Etorphine The therapeutic efficacy of Etorphine can be decreased when used in combination with Meptazinol.
Dextromoramide The therapeutic efficacy of Dextromoramide can be decreased when used in combination with Meptazinol.
Desomorphine The therapeutic efficacy of Desomorphine can be decreased when used in combination with Meptazinol.
Carfentanil The therapeutic efficacy of Carfentanil can be decreased when used in combination with Meptazinol.
Dihydrocodeine The therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Meptazinol.
Alphacetylmethadol The therapeutic efficacy of Alphacetylmethadol can be decreased when used in combination with Meptazinol.
Dihydromorphine The therapeutic efficacy of Dihydromorphine can be decreased when used in combination with Meptazinol.
Ketobemidone The therapeutic efficacy of Ketobemidone can be decreased when used in combination with Meptazinol.
DPDPE The therapeutic efficacy of DPDPE can be decreased when used in combination with Meptazinol.
Lofentanil The therapeutic efficacy of Lofentanil can be decreased when used in combination with Meptazinol.
Opium The therapeutic efficacy of Opium can be decreased when used in combination with Meptazinol.
Normethadone The therapeutic efficacy of Normethadone can be decreased when used in combination with Meptazinol.
Piritramide The therapeutic efficacy of Piritramide can be decreased when used in combination with Meptazinol.
Alphaprodine The therapeutic efficacy of Alphaprodine can be decreased when used in combination with Meptazinol.
Nicomorphine The therapeutic efficacy of Nicomorphine can be decreased when used in combination with Meptazinol.
Phenoperidine The therapeutic efficacy of Phenoperidine can be decreased when used in combination with Meptazinol.
Phenazocine The therapeutic efficacy of Phenazocine can be decreased when used in combination with Meptazinol.
Tilidine The therapeutic efficacy of Tilidine can be decreased when used in combination with Meptazinol.
Carfentanil, C-11 The therapeutic efficacy of Carfentanil, C-11 can be decreased when used in combination with Meptazinol.
Benzhydrocodone The therapeutic efficacy of Benzhydrocodone can be decreased when used in combination with Meptazinol.
Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meptazinol.
Succinylcholine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Meptazinol.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Meptazinol.
Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Meptazinol.
Methylnaltrexone Meptazinol may increase the opioid antagonism activities of Methylnaltrexone.
Naloxegol Meptazinol may increase the opioid antagonism activities of Naloxegol.
Mirtazapine Meptazinol may increase the serotonergic activities of Mirtazapine.
Fluvoxamine The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Fluvoxamine.
Citalopram The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Citalopram.
Duloxetine The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Duloxetine.
Paroxetine The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Paroxetine.
Sertraline The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Sertraline.
Sibutramine The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Sibutramine.
Nefazodone The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Nefazodone.
Zimelidine The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Zimelidine.
Dapoxetine The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Dapoxetine.
Milnacipran The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Milnacipran.
Desvenlafaxine The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Meptazinol.
Seproxetine The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Seproxetine.
Levomilnacipran The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Levomilnacipran.
Indalpine The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Indalpine.
Ritanserin The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Ritanserin.
Alaproclate The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Alaproclate.
Ethanol Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.
Phentermine Phentermine may increase the analgesic activities of Meptazinol.
Pseudoephedrine Pseudoephedrine may increase the analgesic activities of Meptazinol.
Benzphetamine Benzphetamine may increase the analgesic activities of Meptazinol.
Diethylpropion Diethylpropion may increase the analgesic activities of Meptazinol.
Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Lisdexamfetamine.
Mephentermine Mephentermine may increase the analgesic activities of Meptazinol.
MMDA MMDA may increase the analgesic activities of Meptazinol.
Midomafetamine Midomafetamine may increase the analgesic activities of Meptazinol.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Meptazinol.

Target Protein

Cholinesterase BCHE

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul